COREPHARMA
PharmaCOREPHARMA is a pharmaceutical company focused on Cardiovascular, Immunology, Gastroenterology.
COREPHARMA's Key Drugs
COREPHARMA's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
COREPHARMA's Recent FDA Approvals
New NDA/BLA approvals for COREPHARMA over the last two years — novel drugs only, excluding generics and label supplements.
COREPHARMA's Therapeutic Areas
COREPHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COREPHARMA's Top Competitors
COREPHARMA's closest competitors by therapeutic-area and drug-target overlap include MALLINCKRODT, BAUSCH, and LEGACY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COREPHARMA Pipeline Snapshot
Active clinical trials for COREPHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1964-09-22
- Latest
- 2024-11-21
- Applications
- 22